Company
Funding data: Recent Funding. Each amount links to the announcement it came from.
Synchron
Synchron builds implantable Brain-Computer Interfaces, including its first product, Stentrode. These devices are delivered through a blood vessel and record neural signals to restore communication and independence. Synchron's customers are people living with paralysis and those with severe motor impairments.
Rounds
| Date | Stage | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| Jun 29, 2026 | Series B+ | $275M | — | Alumni Ventures, ARCH Venture Partners, General Atlantic, Khosla Ventures, Medtronic | neurotech.com ↗ |
| Nov 6, 2025 | Series B+ | $200M | — | — | fundraisingfox.com ↗ |
| Dec 15, 2022 | Series B+ | $75M | — | — | massdevice.com ↗ |
| Jun 3, 2021 | Series B+ | $40M | — | — | finsmes.com ↗ |
| Apr 4, 2017 | Series A | $10M | — | — | fiercebiotech.com ↗ |
About
- Website
- synchron.com
- X
- @synchroninc
- Based in
- Brooklyn, United States
- Founded
- 2016
Founders
- Nicholas OpieFounder
- Thomas OxleyFounder
- Andy RasdalChief of Staff
- Kurt HaggstromChief Commercial Officer
- Mark BristerVice President of Research and Development
- Riki BanerjeeChief Technology Officer
Investors
Alumni Ventures · ARCH Venture Partners · Bezos Expeditions · DARPA · Double Point Ventures · General Advance · General Atlantic · ID8 Investments · IQT · K5 Global · Khosla Ventures · Medtronic · METIS innovative · Moore Strategic Ventures · National Reconstruction Fund Corporation · Neurotechnology Investors · Project X · Protocol Labs · Qatar Investment Authority · re.Mind Capital · Reliance Industries · Shanda Group · Subversive Capital · T.Rx Capital · Thomas Reardon · University of Melbourne